Catalyst Pharmaceuticals Inc (CPRX)

Return on total capital

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 134,643 113,492 76,238 78,130 80,017 68,511 130,867 112,740 101,101 83,728 72,522 59,745 52,240 48,045 45,853 40,439 41,338 40,727 42,800 43,376
Long-term debt US$ in thousands — — — — — — — — — — — — — — — — — — — —
Total stockholders’ equity US$ in thousands 727,632 660,941 608,655 561,412 387,881 348,548 375,294 333,661 300,421 270,041 241,092 220,221 206,831 198,661 188,944 178,651 169,598 156,628 111,201 99,676
Return on total capital 18.50% 17.17% 12.53% 13.92% 20.63% 19.66% 34.87% 33.79% 33.65% 31.01% 30.08% 27.13% 25.26% 24.18% 24.27% 22.64% 24.37% 26.00% 38.49% 43.52%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $134,643K ÷ ($—K + $727,632K)
= 18.50%

Catalyst Pharmaceuticals Inc's return on total capital has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ratio started at a relatively high level of 43.52% in March 2020, indicating efficient utilization of both debt and equity to generate profits. However, the return on total capital decreased to 18.50% by December 31, 2024.

During this period, the ratio experienced both ups and downs, reaching a peak of 34.87% in June 30, 2023, and a low of 12.53% in June 30, 2024. The variations in return on total capital suggest changes in the company's profitability and efficiency in utilizing its capital resources.

Further analysis would be needed to understand the factors behind these fluctuations and whether they are driven by operational performance, capital structure changes, or other external factors impacting the company's financial performance.